Enantia Custom Synthesis, Asymmetric Chemistry and Co-Crystallisation

Enantia is a company devoted to chemical research and process development, custom synthesis and crystal engineering, with a strong focus on asymmetric chemistry and co-crystallisation technologies.

Our mission is to provide fully integrated chemistry services for the fine chemical, pharmaceutical and biotech sectors. We can contribute all the way from initial research in medicinal chemistry or route scouting to any phase of the chemical process R&D. We like to be seen not only as a mere service provider, but as a committed team to pursue the success of our clients’ projects.

We can handle almost any kind of chemical project related to organic chemistry, both from a technical and project management point of view. Our chemistry expertise has an industry-leading reputation. The most challenging projects are our day-to-day routine.

API process development

Enantia’s staff has extensive experience in chemical research and process development and has created a number of chemical processes running today at industrial scale. Clients seeking to improve troublesome steps in a process, or to redesign an entire chemical route for one of their potential APIs or key intermediates, will value the team at Enantia. Our goal is to develop for our clients scalable chemical processes that are safe, environmentally sound, robust and cost-effective. We can contribute to:

  • Ensure a sustainable process for long-term, large-scale production
  • Optimise reaction parameters (reagent stoichiometry, temperatures and concentrations)
  • Maximise catalyst recycling
  • Combine steps to ‘telescope’ and simplify the process
  • Optimise purification by identifying key solid intermediates
  • Optimise recrystallisation to ensure high product recovery and consistent specifications
  • Perfect analytical support for reaction control and product specification
  • Identification and synthesis of impurities
  • Validation of process parameter ranges

Custom synthesis

We are able to rapidly satisfy custom synthesis requests from mg up to kilo-lab scale in-house, such as the synthesis of:

  • APIs and intermediates
  • Lead compounds for drug discovery and medicinal chemistry projects
  • Samples and reference compounds
  • Metabolites
  • Repeat samples
  • Reagents, scaffolds and building blocks

If you need to produce kilograms or tons of an API or intermediate Enantia can help you, taking care of the production through a network of validated manufacturing partners, both cGMP and non-cGMP.

Crystal engineering and co-crystals

Co-crystal solid forms are gaining increased significance in the pharmaceutical and chemical industry as an efficient way to modify the physicochemical properties of organic molecules like APIs, intermediates and other synthetic products.

The big advantage of co-crystals compared with salts is that co-crystallisation is also applicable to non-ionisable molecules where salt formation is not possible.

Benefits of co-crystallisation

Co-crystals offer great potential in various fields:

  • Chiral resolution: whether a molecule is ionisable or not, selective diastereomeric co-crystallisation can be attainable using an enantiomerically pure coformer
  • Separation and purification: co-crystals can be a good option, especially with non-ionisable products, to purify some intermediates, consequently avoiding expensive chromatographic techniques
  • Crystallisation of non-solid products: liquids, pastes and oily products can become a solid form by means of co-crystallisation, leading to more robust and efficient manufacturing processes
  • Improvement of solid-state properties (of APIs and other organic substances): several important characteristics of pharmaceutical substances like solubility, bioavailability, stability, hygroscopicity, morphology, filtration and flowability can be modified by means of co-crystal formation

About Enantia

Today, with over 40 employees, Enantia has become a reference provider for life sciences companies that seek not only scientific and technical excellence but also a simple and candid way to do business.

With a flexible commercial model, we can execute projects through full time equivalent (FTE) service agreements and also through a variety of different approaches such as fee-per-success, fee-per-project or through a shared risk approach. Flexibility and adaptability to our clients’ demands is one of our key assets.

After the signature of a CDA, a free pre-assessment of the project is always carried out and we will only accept projects where we perceive a realistic probability of success.

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic Alliance for Marketing of Elafin in Asia, Africa and South America

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

White Papers

Cocrystals in the Pharmaceutical and Fine Chemicals Industry: From an Option to an Opportunity

In the drug discovery and development arena it is well known that the choice of the right solid form can have a dramatic influence on the successful development of an active pharmaceutical ingredient (API).

Address
Enantia SL

Baldiri Reixac 10

Barcelona

08028

Spain

+34 93 403 48 37 +34 93 403 48 38 www.enantia.com

Enantia Images

Products and Services

Video

Press Release

8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Enantia SL

Baldiri Reixac 10

Barcelona

08028

Spain

+34 93 403 48 37 +34 93 403 48 38 www.enantia.com

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.